T-DXD resistant HER2-positive

Clinical trials for T-DXD resistant HER2-positive explained in plain language.

Never miss a new study

Get alerted when new T-DXD resistant HER2-positive trials appear

Sign up with your email to follow new studies for T-DXD resistant HER2-positive, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

Can a RAGE inhibitor revive a failing breast cancer treatment?

Disease control Not yet recruiting

This trial is testing whether adding azeliragon, a RAGE inhibitor, to the drug T-DXd can help people with HER2-positive or HER2-low metastatic breast cancer whose cancer has progressed despite prior T-DXd treatment. The study will first find the safest dose of the combination, th…

Matched conditions: T-DXD RESISTANT HER2-POSITIVE

Phase 1/2 • Sponsor: The Methodist Hospital Research Institute • Aim: Disease control

Last updated Aug 27, 2026 00:00 UTC

T-DXD resistant HER2-positive

Get alerted when new T-DXD resistant HER2-positive trials appear

Can a RAGE inhibitor revive a failing breast cancer treatment?